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Background: Aprotinin reduces blood loss after cardiopulmonary bypass. 
Although there can be little doubt about the efficacy of aprotinin, its safety 
has been questioned recently and is still under investigation. Because of the 
potential for complications and the high cost, a selective strategy limiting 
drug delivery to patients with established postoperative bleeding will be 
more reasonable. Methods: In a prospective, randomized, double-blind trial 
we studied the effect of postoperative low-dose (2 million kallikrein 
inactivator units) aprotinin o blood loss and transfusion requirements in 
patients undergoing cardiopulmonary bypass. Fifty-seven patients were 
randomly assigned to two groups: aprotinin or placebo. Results: The two 
groups were comparable in all demographic and surgical variables. Post- 
operative chest tube drainage was significantly less in the aprotinin group 
than in the placebo group (410 ml vs 696 ml, p < 0.01). The use of 
homologous blood products was significantly less in the aprotinin group 
than in the placebo group (0.4 + 0.5 unit vs 1.7 -+ 0.9 unit for packed red 
blood cells and 0.8 -- 1.3 unit vs 2.3 - 1.6 unit for fresh frozen plasma). 
Conclusions: Our results suggest hat postoperative aprotinin reduces blood 
loss and transfusion requirements and provides the opportunity to restrict 
its use selectively to patients with excessive postoperative bleeding. 
(J Thorac Cardiovasc Surg 1996;112:1462-7) 
T he serine proteinase inhibitor aprotinin has been demonstrated to decrease postoperative bleeding 
and transfusion requirements in patients undergo- 
ing cardiac operations with cardiopulmonary b pass 
(CPB). 1 Since the first description of high-dose 
aprotinin for prophylaxis against excessive postop- 
erative bleeding, numerous tudies with different 
dosage protocols have been published that con- 
firmed the efficacy of the drug. 2-4 It has been 
suggested that aprotinin should begiven before and 
during CPB to produce a constant plasma concen- 
tration to prevent fibrinolysis and to protect platelet 
function. 
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Although initial clinical reports suggested aproti- 
nin to be safe with few side effects, evidence has 
recently appeared that questions its overall safety 
for prophylactic systemic therapy. Adverse effects on 
coronary artery bypass graft patency, renal impair- 
ment, anaphylactic reactions during subsequent ex- 
posures, and disseminated intravascular coagulation 
after profound hypothermia have been attributed to 
the systemic use of aprotinin. 5-7 The cost of a 
high-dose aprotinin regimen is equivalent to the cost 
of about 8 to 10 units of blood? The high cost of 
aprotinin restricts routine prophylactic use in many 
centers, especially in the United States, because of 
potential limitations in reimbursement to all health 
care providers. 9 
Excessive bleeding after cardiac operations is a 
major concern for cardiac surgical teams. It has 
been reported in 5% to 25% of patients undergoing 
CPB. 1° This figure becomes more important i  view 
of the increasing number of reoperations and emer- 
gency surgical procedures during which patients are 
still under the effect of antiplatelet or antifibrinolytic 
agents. However, only 3% to 5% of all patients 
undergoing cardiac operations require reoperation 
for bleeding. 11 This supports our contention that the 
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Table I. Operative procedures performed 
Aprotinin group Placebo group 
Operations (n : 29) (n = 28) 
CABG 19 17 
AVR or MVR 5 8 
DVR 4 3 
CABG-AVR 1 - -  
CABG, Coronary artery bypass grafting; AVR, aortic valve replacement; 
MVR, mitral valve replacement; DVR, double valve replacement (AVR 
and MVR). 
Table I I . Patient characteristics* 
Variable Aprotinin Placebo 
n 29 28 
Age (yr) 51.6 _+ 15.4 48.2 +_ 14.2 
Male/female 21/8 19/9 
Preop. aspirin (n) 14 13 
CPB time (min) 97.5 -+ 45.6 78.4 _+ 25.5 
No. of grafts 2.8 _+ 0.7 2.6 + 0.7 
No. of ITAs 0.9 _+ 0.2 0.7 + 0.4 
*Values are mean -+ standard deviation. No significant differences were 
observed inpatient characteristics. 
majority of patients who are treated with aprotinin 
are unnecessarily exposed to side effects of the drug. 
It would be prudent to apply aprotinin on a more 
selective basis to avoid adverse reactions and unnec- 
essary prophylactic use. One effective strategy to 
achieve these goals would be to restrict the use of 
aprotinin exclusively to patients with established 
postoperative bleeding. Angelini and colleagues 12 
reported six cases in which aprotinin postoperatively 
reduced bleeding that failed to respond to conven- 
tional treatment. More recently, Kallis and associ- 
ates 13 demonstrated that postoperative use of apro- 
tinin in patients with established bleeding reduced 
blood loss. However, further studies are warranted 
on this topic. 
This clinical randomized ouble-blind study was 
conducted to investigate the effect of aprotinin given 
postoperatively on blood loss and transfusion re- 
quirements in patients undergoing cardiac opera- 
tions. 
Patients and methods 
A randomized, double-blind, placebo-controlled study 
was carried out to compare the efficacy of postoperative 
aprotinin and placebo to decrease bleeding and transfu- 
sion requirements on patients undergoing cardiac opera- 
tions with CPB. Informed consent was obtained from all 
patients. Patients who had previous exposure to aprotinin 
or who had received systemic or topical aprotinin during 
the operation were excluded from the study. Fifty-seven 
patients were included in the study and were randomized 
to receive aprotinin or placebo by means of the table of 
random numbers. 
Aprotinin group. Patients in the aprotinin group re- 
ceived a bolus of 2 × 106 kallikrein inhibiting units (KIU) 
of aprotinin (280 mg) (Trasylol; Bayer AG, Leverkusen, 
Germany) infused over 15 minutes when they arrived in 
the intensive care unit (ICU). 
Placebo group. Patients in the placebo group received 
an equal volume of normal saline solution at all corre- 
sponding times. 
The operative procedures performed are defined in 
Table I. All patients were operated on and cared for by 
the same team. 
The anesthetic management and conduct of CPB were 
standardized. The extracorporeal circuit consisted of a 
hollow-fiber membrane oxygenator (Terumo Copiox E, 
Terumo Co., Tokyo, Japan). Polyvinyl chloride tubing was 
used throughout the circuit except for the roller pump 
tubing, which was silicone rubber. Before CPB patients 
were given 300 U bovine lung heparin per kilogram of 
body weight; whenever the activated clotting time was 
shorter than 480 seconds, additional doses of heparin 
were given. 
Mild to moderate hypothermia, cold crystalloid car- 
dioplegic solution (Plegisol, Abbott Laboratories, North 
Chicago, Ill.) for induction of cardioplegia, nd cold blood 
cardioplegic solution (infused every 20 minutes) for main- 
tenance were used for myocardial protection. Before 
unclamping the aorta, we administered warm blood car- 
dioplegic solution (500 ml at 37 ° C). The cardioplegic 
solution (either crystalloid or blood cardioplegic solution) 
was returned to the circuit. Left internal thoracic artery 
grafts were used routinely in patients undergoing coronary 
artery bypass grafting. The saphenous vein was harvested 
as needed. During systemic heparinization, blood was 
routinely returned to the pump-oxygenator and reinfused. 
Finally, all blood remaining in the venous tubing and in 
the oxygenator after CPB was collected and reinfused 
when necessary, during the operation or in the ICU. At 
the end of CPB, the heparin effect was reversed with 
protamine sulfate at a 1:1 ratio. 
Hemoglobin concentration, hematocrit value, platelet 
count, prothrombin time, activated partial thromboplastin 
time, and fibrinogen levels were measured in all patients 
before the operation and when they arrived at the ICU. 
The shed mediastinal blood was collected in a commer- 
cially available volumetric collection system, and the 
amount was measured every half hour for the first day and 
hourly thereafter. The mediastinal and thoracic drains 
were removed when the total drainage was less than 100 
ml over the previous 8 hours. 
Homologous packed red cells were administered only 
when the hematocrit value fell to less than 24%. Patients 
received fresh frozen plasma when excessive blood loss 
was accompanied by a prolonged (>1.5 times normal 
values) prothrombin time. Additional protamine was ad- 
ministered if the activated clotting time/control ratio was 
greater than 1.5. Platelet ransfusions were not used. Shed 
blood was not autotransfused in any of the patients during 
this study. Reoperation for bleeding was undertaken if the 
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Fig. 1. A, Hourly blood loss for the first 6 hours after the initiation of aprotinin or placebo. Values are 
shown as mean _+ standard error of the mean. B, Cumulative blood loss in the first 6 hours. 
blood loss exceeded 500 ml for two consecutive hours 
without signs of decreasing despite appropriate ther- 
apy. 
CPB time, total operation time, amount of total chest 
tube drainage, prevalence of reoperation for bleeding, 
cause of bleeding, and need for donor blood transfusion 
or fresh frozen plasma were recorded for all patients. The 
course of the blood hemoglobin content during hospital- 
ization was analyzed in each patient. 
Sample size was calculated by an expected ifference 
in blood loss between groups of 250 ml, standard 
deviation of 250 ml, c~ = 0.05,/3 = 0.05, with n = 28 for 
each of the groups. All results are expressed as the 
mean values _+ standard eviation. Statistical compari- 
sons were made by means of the Student's t test. A p 
value less than 0.05 was considered to be statistically 
significant. Statistical analyses were made with the use 
of the Primer of Biostatistics: The Program Version 
3.02 (McGraw-Hill, Inc., New York, N.Y.) statistical 
software package. 
Results 
No differences were found between the aprot inin 
and placebo groups in pat ient  age, sex, CPB time, 
and durat ion of operat ion.  Four teen  patients in the 
aprot inin group and 13 in the placebo group had 
taken aspirin up until 7 days before the operat ion.  
Also, the number  of bypass grafts and the number  of 
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Table III. Total transfusion requirement 
Variable Aprotinin Placebo p Value 
Packed RBC 0.45 _+ 0.50 1.70 _+ 0.9 <0.01 
(units per patient) 
FFP 0.80 _+ 1.36 2.35 _+ 1.6 <0.01 
(units per patient) 
Patients receiving 37 64 <0.01 
transfusions (%) 
Values are mean -+ standard eviation. 
internal thoracic arteries used per patient in patients 
undergoing coronary artery bypass graft operations 
were not statistically different between the groups 
(Table II). The types of operative procedures per- 
formed were comparable for the two groups. Except 
for one operation in the aprotinin group, these 
procedures were initial operations. There were also 
no significant differences between the groups in 
postoperative h modynamics, duration of stay in the 
ICU, and postoperative hospital stay (data not 
shown). One patient in the aprotinin group was 
reoperated on for excessive bleeding. A sternal 
bleeding site was identified. There were no instances 
of renal impairment, perioperative myocardial in- 
farction, or allergic reactions to aprotinin. 
Fig. 1 shows the course of blood loss after com- 
mencement of aprotinin therapy. Postoperative 
blood loss at 1 hour was 82.5 _+ 60.7 ml in the 
placebo group and was significantly lower in 
the aprotinin group (40.7 _+ 51.5 ml). The trend in 
the reduction of blood loss continued in the 
aprotinin group throughout he first 6 hours and 
thereafter. Significantly less postoperative chest 
tube drainage was noted in the aprotinin group 
(including one patient who required reentry for 
surgical bleeding) than in the placebo group at the 
first 24-hour measurement (410.5 _+ 174.8 ml vs 
696.2 _+ 247.7 ml, p < 0.01) and at the removal of 
chest tubes (436.8 _+ 188.2 ml vs 852.5 _+ 336.9 ml, 
p < 0.01). The 95% confidence interval for differ- 
ence in total blood loss was 271.4 to 559.8 ml. 
The use of banked donor blood products during 
the operation was not significantly different be- 
tween the groups. Hemoglobin values were similar 
in the two groups on arrival in the ICU, allowing 
a direct comparison between groups with regard 
to postoperative use of blood products. However, 
the transfusion requirement was significantly 
lower in the aprotinin group than in the placebo 
group (Table III). Only 37% of aprotinin-treated 
patients required donor blood or blood products 
Table IV. Hematologic values and coagulation tests 
Aprotinin Placebo 
Hemoglobin (gm/dl) 
Preoperative 13.2 ± 1.1 12.5 _+ 1.4 
Postoperative 8.9 _+ 1.1 8.6 + 1.2 
Platelets (109/L) 
Preoperative 287.2 ± 84.9 244.8 _+ 88.6 
Postoperative 136.2 _+ 50.9 138.0 _+ 60.6 
Fibrinogen (mg/dl) 
Preoperative 424.0 ± 92.8 374.1 ± 140.3 
Postoperative 312.3 _+ 72.8 290.9 _+ 84.7 
Prothrombin time (sec) 
Preoperative 13.2 _+ 0.5 13.3 _+ 1.2 
Postoperative 13.3 + 0.8 13.7 _+ 1.0 
Partial thromboplastin time (sec) 
Preoperative 36.8 _+ 4.2 35.3 +_ 3.2 
Postoperative 38.8 _+ 2.9 39.5 ± 2.2 
*Values are mean -+ standard eviation. No significant differences were 
observed. 
in comparison with 64% of those in the placebo 
group. 
There were no statistically significant differences 
between the two groups with regard to platelet 
count, prothrombin time, activated partial thrombo- 
plastin time, and fibrinogen level before and early 
after the operation when patients arrived in the ICU 
(Table IV). 
Discussion 
Of all the drugs used to minimize postoperative 
bleeding, aprotinin has been the most successful. No 
other blood conservation agent has a comparable 
efficacy.9, 14 However, a consensus has not been 
reached concerning patient selection and dosage 
regimen. Numerous reports have shown the benefits 
of both high-dose and low-dose regimens. Because 
of the potential for complications and the high cost 
of aprotinin, it is logical to use aprotinin on a more 
selective basis, that is, in patients with established 
postoperative bleeding. 
This study demonstrated that postoperative blood 
loss and transfusion requirements were significantly 
lower in the aprotinin group than in the placebo 
group. The satisfactory reduction in postoperative 
blood loss in the aprotinin group prompted us to 
analyze the results of blood loss in a smaller sub- 
group of patients undergoing coronary artery bypass 
who continued to take aspirin until 1 week before 
the operation. Aprotinin treatment in these patients 
significantly decreased the postoperative blood loss. 
The mean blood loss in the aprotinin group was 
460.7 _ 174.7 ml and in the placebo group, 960.7 _+ 
1466 ~ifek et aL 
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305.2 ml; (p < 0.01). In the present study we used 
the low-dose regimen (2 million KIU) because 
low-dose aprotinin is sufficient to obtain the re- 
quired antiplasmin effect and to preserve glycopro- 
tein Ib receptors. 15' 16 The reduction of postopera- 
tive blood loss, to our surprise, is comparable with 
that in other studies in which aprotinin was applied 
prophylactically.i, 2 The most effective time to ad- 
minister aprotinin during cardiac operations is still 
unknown. It has been universally recommended and 
accepted that aprotinin should be given before CPB 
and throughout the surgical procedure to be effec- 
tive.17, 18 Gram and colleagues 19suggested that sig- 
nificant amounts of tissue-type plasminogen activa- 
tor are incorporated into fibrin generated after 
neutralization of heparin and thereby may cause the 
degradation of cross-linked fibrin until at least 24 
hours after the operation, although tissue-type plas- 
minogen activator has returned to baseline levels 
much earlier. Valen and associates 2°also reported 
that increased fibrinolytic activity persists after CPB. 
The presence of fibrin or fibrin monomers timu- 
lates fibrinolytic activity 100-fold. 21 This increased 
activity creates a positive feedback cascade and 
increases the risk of postoperative bleeding. Apro- 
tinin may influence hyperfibrinolysis n the early 
postoperative period. However, quantification of 
plasmin levels is essential to detect he postopera- 
tive fibrinolytic state and aprotinin effect. 
Kallis and associates 13 have recently demon- 
strated the efficacy of aprotinin on hemostasis when 
used postoperatively on patients who bled signifi- 
cantly. The tissue plasminogen activator antigen 
decreased and fibrinogen level increased in the 
aprotinin group. Aprotinin also increased the plate- 
let surface expression of glycoprotein Ib (36% vs 
5%, p < 0.01) and maintained the platelet von 
Willebrand factor activity. They suggested that apro- 
tinin, by inhibiting excessive fibrinolysis and reduc- 
ing plasmin levels, allows replenishment of the 
platelet surface glycoprotein Ib receptors from in- 
traplatelet pools. Michelson and Barnard 22 also 
have shown that platelets recover from plasmin as 
soon as it is neutralized by redistribution of the 
platelet glycoprotein Ib receptor. On the basis of 
current information, one could expect hat postop- 
erative aprotinin would restore platelet function 
through its antiplasmin effect. 
The intact endothelium is involved in the regula- 
tion of hemostasis and thrombosis. It is known that 
endothelial dysfunction occurs systemically during 
CPB. 23 Aprotinin has been shown to inactivate 
protein C, which is the major regulatory protein of 
thrombus formation. 24 Besides controlling the 
thrombin formation, protein C promotes fibrinolysis 
by inactivating the plasminogen activator inhibi- 
tors. 25 The time course of endothelial dysfunction 
has not been established. Endothelial dysfunction of 
sublethal and long-lasting character may occur even 
without morphologic changes 23 and cause leakage of 
tissue-type plasminogen activator stores after CPB, 
resulting in a hyperfibrinolytic state. Postoperative 
aprotinin may also exert an antifibrinolytic action by 
modulating endothelial cell function. However, the 
mechanism of this complex interaction requires 
more comprehensive investigations. 
Conclusions 
1. Aprotinin is effective ven if administered after 
activation of the hemostatic system, with a conse- 
quent significant reduction in blood loss and trans- 
fusion requirements. 
2. Efficacy of postoperative infusion also provides 
the opportunity to minimize the overzealous use of 
prophylactic aprotinin and restrict its use selectively 
to patients with established postoperative bleeding. 
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